Epizyme (Epizyme) Notes Receivable : $0.00 Mil (As of Jun. 2022)

View and export this data going back to 2013. Start your Free Trial

What is Epizyme Notes Receivable?

Epizyme's Notes Receivable for the quarter that ended in Jun. 2022 was $0.00 Mil.

Epizyme Notes Receivable Historical Data

The historical data trend for Epizyme's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epizyme Notes Receivable Chart

Epizyme Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Notes Receivable

Get a 7-Day Free Trial

Epizyme Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
Notes Receivable	Get a 7-Day Free Trial															-	-	-	-	-

Epizyme Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Epizyme Notes Receivable Related Terms

Thank you for viewing the detailed overview of Epizyme's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Epizyme (Epizyme) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Epizyme Inc (NAS:EPZM) » Definitions » Notes Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

400 Technology Square, 4th Floor, Cambridge, MA, USA, 02139

Website

https://www.epizyme.com

Epizyme Inc is a clinical-stage biopharmaceutical company that is committed to rewriting treatment for cancer and other serious diseases through discovering, developing, and commercializing novel epigenetic medicines. Its product candidates include one approved product, TAZVERIK (tazemetostat), an inhibitor of the EZH2. The company is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias and PRMT5 inhibitor.

Executives

Jeffery Kutok	officer: Chief Scientific Officer	784 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Jerald Korn	officer: Chief Operating Officer	128 GORDON RD, NEWTON MA 02468
Joseph Beaulieu	officer: Corporate Controller	C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Shefali Agarwal	officer: Chief Medical Officer	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Royalty Pharma Investments 2019 Icav	director, 10 percent owner	C/O RP MANAGEMENT, LLC 100 E. 59TH ST., 33RD FLOOR NEW YORK NY 10022
Pablo G. Legorreta	director	110 E 59TH STREET, SUITE 3300, NEW YORK NY 10022
Carol Stuckley	director	C/O CENTESSA PHARMACEUTICALS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Roy A Beveridge,	director	500 W MAIN ST, LOUISVILLE KY 40202
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Robert B Bazemore	director, officer: President & CEO	33 HAYDEN AVE, LEXINGTON MA 02421
Matthew Ros	officer: Chief Operating Officer	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Paolo Tombesi	officer: Chief Financial Officer	10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Victoria Vakiener	officer: Chief Commercial Officer	C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Carl Goldfischer	director	161 WEST 61ST STREET, NEW YORK NY 10022
Rp Management, Llc	director	110 EAST 59TH STREET SUITE 3300 NEW YORK NY 10022